RT Journal Article
SR Electronic
T1 OpenSAFELY: impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.03.20243535
DO 10.1101/2020.12.03.20243535
A1 ,
A1 Curtis, Helen J
A1 MacKenna, Brian
A1 Walker, Alex J
A1 Croker, Richard
A1 Mehrkar, Amir
A1 Morton, Caroline E
A1 Bacon, Seb
A1 Hickman, George
A1 Inglesby, Peter
A1 Bates, Chris
A1 Evans, David
A1 Ward, Tom
A1 Cockburn, Jonathan
A1 Davy, Simon
A1 Bhaskaran, Krishnan
A1 Schultze, Anna
A1 Rentsch, Christopher T
A1 Williamson, Elizabeth
A1 Hulme, William
A1 McDonald, Helen I
A1 Tomlinson, Laurie
A1 Mathur, Rohini
A1 Drysdale, Henry
A1 Eggo, Rosalind M
A1 Wing, Kevin
A1 Wong, Angel YS
A1 Forbes, Harriet
A1 Parry, John
A1 Hester, Frank
A1 Harper, Sam
A1 Evans, Stephen JW
A1 Douglas, Ian J
A1 Smeeth, Liam
A1 Goldacre, Ben
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.03.20243535.abstract
AB Background Early in the COVID-19 pandemic the NHS recommended that appropriate patients anticoagulated with warfarin should be switched to direct acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately co-prescribed two anticoagulants following a medication change, and associated monitoring.Objective To describe which people were switched from warfarin to DOACs; identify potentially unsafe co-prescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic.Methods Working on behalf of NHS England we conducted a population cohort based study using routine clinical data from >17 million adults in England.Results 20,000 of 164,000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in co-prescribing of warfarin and DOACs from typically 50-100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. INR testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420).Conclusions Increased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people co-prescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: BG has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK (HDRUK), the Health Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. IJD has received unrestricted research grants and holds shares in GlaxoSmithKline (GSK).Funding StatementThe OpenSAFELY platform is supported by funding from UKRI MRC and Wellcome trust. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. BGs work on better use of data in healthcare more broadly is currently funded in part by: NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley the MohnWestlake Foundation NHS England and the Health Foundation; all DataLab staff are supported by BGs grants on this work. LS reports grants from Wellcome MRC NIHR UKRI British Council GSK British Heart Foundation and Diabetes UK outside this work. AS is employed by LSHTM on a fellowship sponsored by GSK. KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society. HIM is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. RM holds a fellowship funded by the Wellcome Trust. AYSW holds a fellowship from BHF. EW holds grants from MRC. IJD holds grants from NIHR and GSK. HF holds a UKRI fellowship. RE is funded by HDR-UK and the MRC. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code for the OpenSAFELY platform, and for data management and analyses for this study, are available for inspection and reuse under open licenses on GitHub (https://github.com/opensafely/anticoagulant-switching-research). All codelists are available for inspection and re-use from https://codelists.opensafely.org/. Patient